Analyzing genetic changes in patients with acute myeloid leukemia during treatment
Official title: Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06764459 · Data updated 2026-11-12
This study is trying to see how genetic changes in acute myeloid leukemia patients with FLT3 mutations affect their response to treatment, to help identify those who might not respond well.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Status | Recruiting |
| Started | March 15, 2023 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | January 30, 2025 |
| Trial ID | NCT06764459 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with FLT3 mutated acute myeloid leukemia.
✕Probably not a fit
Patients who respond well to therapy and do not have FLT3 mutations may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on patients with acute myeloid leukemia (AML) who have mutations in the FLT3 gene. It employs single-cell molecular characterization techniques to identify and track the evolution of cancer cell clones and subclones throughout treatment. By understanding how these genetic profiles change under therapeutic pressure, the study aims to uncover mechanisms of resistance to FLT3 inhibitors. Ultimately, the goal is to develop new molecular markers that can help identify patients who are likely to be resistant to treatment early on, thereby improving their therapeutic management.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with FLT3 mutated AML.
How similar studies have gone: Other studies have shown promise in using molecular characterization to understand treatment resistance in leukemia, making this approach both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * FLT3 mutated Exclusion Criteria: * Respoder to therapy
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola
Bologna, Italy Recruiting
Study contacts
- Principal investigator: Emanuela Ottaviani, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Emanuela Ottaviani, MD
- Email: emanuela.ottaviani@aosp.bo.it
- Phone: 0039 0512144055
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized T cells engineered to target TP53 or RAS mutations in blood cancers
This trial will try using a patient's own T cells, modified to recognize specific TP53 or RAS mutations, to treat adults with certain blood cancers.
-
Decision support for older adults with acute myeloid leukemia and their caregivers
This will test a decision-support program (UR-GOAL) to help people 60 and older with newly diagnosed AML and their caregivers make treatment decisions.
-
New approach to stem cell transplant for high-risk leukemia patients
This study is testing a new type of stem cell transplant for high-risk leukemia patients to see if it can help them recover better and avoid complications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.